ValueQ4, 24TTMSelling/general/admin expenses158.25 M610.47 MResearch & development198.94 M681.81 MOperating income415.24 M-515.07 MNon-Operating Income, Total27.83 M280.07 MInterest expense, net of interest capitalized——Non-Operating Income, excl. Interest Expenses15.26 M276.06 MUnusual income/expense12.57 M4.01 MPretax income454.1 M-264.58 MEquity in earnings——Taxes98.35 M133.33 MNon-controlling/minority interest52.75 M-98.14 MAfter tax other income/expense5.52 M-1.83 MNet income before discontinued operations302.99 M-299.77 MDiscontinued operations00Net income302.99 M-299.77 MDilution adjustment——Preferred dividends——Diluted net income available to common stockholders302.99 M-299.77 MBasic earnings per share (Basic EPS)0.45-0.43Diluted earnings per share (Diluted EPS)0.34-0.54Average basic shares outstanding693.86 M—Diluted shares outstanding693.86 M—EBITDA-354.36 M-1.28 BEBIT-355 M-1.29 BCost of revenue——Other cost of goods sold——Depreciation & amortization (cash flow)638 K3.35 M
Roivant Sciences Ltd. - Common Shares
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.